

48. Warren BL, Eid A, Singer P, et al. KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. *JAMA*. 2001;286(15):1869-1878
49. Kienast J, Juers M, Wiedermann CJ, et al. KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. *J Thromb Haemost*. 2006;4(01):90-97.
50. Tagami T. Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation: reevaluation of a "pendulum effect" drug using a nationwide database. *J Thromb Haemost*. 2018;16(3):458-61.
51. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. *Shock*. 2011;35(4):349-54.
52. Vincent JL, Francois B, Zabolotskikh I, et al. SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET Randomized Clinical Trial. *JAMA*. 2019;321(20):1993-2002.
53. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med*. 2001;344(10):699-709.
54. Nadel S, Goldstein B, Williams MD, et al. REsearching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective (RESOLVE) Study Group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. *Lancet*. 2007;369(9564):836-843.
55. Abraham E, Laterre PF, Garg R, et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (address) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and low risk of death. *N Engl J Med*. 2005;353(13):1332-1341.
56. Ranieri VM, Thompson BT, Barie PS, et al. PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. *N Engl J Med*. 2012;366(22):2055-2064.
57. Abraham E, Reinhart K, Opal S, et al. OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. *JAMA*. 2003;290(2):238-247.
58. Wunderink RG, Laterre PF, Francois B, et al. CAPTIVATE Trial Group. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. *Am J Respir Crit Care Med*. 2011;183(11):1561-1568
59. Levi M, Scully M. How I treat disseminated intravascular coagulation. *Blood*. 2018;131:845-54.
60. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. *J Intensive Care*. 2014;2:15.

## ON-LINE KURZ

# Nové trendy v léčbě migrény a jiné bolesti

### PŘEDNÁŠKY

- **Úvod** – MUDr. Tomáš Nežádal, Ph.D.
- **Migréna u praktického lékaře** – MUDr. Irena Novotná
- **Bolest dolní končetiny, (pseudo)radikulární syndrom** – MUDr. Luboš Dušek
- **Bolest zad – klinický algoritmus, možnosti intervenční léčby** – MUDr. Michal Adam
- **Bolest hlavy – jde opravdu o migrénu?** – MUDr. Irena Novotná

### ODBORNÝ GARANT

MUDr. Tomáš Nežádal, Ph.D.  
Ústřední vojenská nemocnice –  
Vojenská fakultní nemocnice Praha

POČET  
KREDITŮ **2**

Registrace  
**ZDARMA**

### TERMÍN

duben 2023  
až březen 2024

dostupný na  
[online.solen.cz](http://online.solen.cz)

MEDIÁLNÍ  
PARTNER

Medicína  
pro praxi

Vnitřní  
lékařství

